Top Health Tech Companies in Melbourne (50)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
For more than two decades, Imprivata has been redefining how life- and mission-critical industries secure and manage digital identities. We empower healthcare and enterprise organizations to enable fast, compliant, and secure access to technology—allowing clinicians and staff to stay focused on what matters most: patient care and operational excellence. Our digital identity platform is purpose-built for complex environments where every second...
Imprivata's Top Stability & Growth Strengths
Strong Revenue Growth: Top line is described as expanding steadily in recent years, with continued growth expected. Separate reporting cites roughly $500 million in annual revenue and rapid momentum, even as exact figures vary.
Healthy Cash Flow: Cash generation has improved enough for a late‑2025 credit rating upgrade, with projections to produce over $100 million in free cash flow within the next 12–24 months. Leverage is expected to trend down alongside strong margins.
Customer Loyalty & Retention: Retention is characterized as consistently high with net expansion of spend, signaling durable relationships and effective cross‑sell within the installed base. A sizable customer count (over 4,000 organizations) supports stickiness across regions.
The International SOS Group of Companies is in the business of saving lives, protecting global workforces from health and security threats. We deliver customised health, security risk management and wellbeing solutions to fuel our clients’ growth and productivity. In the event of extreme weather, an epidemic or a security incident, we provide an immediate response providing peace of mind. Our...
ProPharma is the premier Research Consulting Organization (RCO), delivering fully customizable consulting solutions to empower biotech, med device, and pharmaceutical organizations of all sizes to advance scientific breakthroughs confidently and introduce new therapies. With over 20 years of expertise in regulatory sciences, clinical research solutions, quality & compliance, pharmacovigilance, medical information, and R&D technology, ProPharma partners with clients across the...
Teladoc Health is on a mission to empower all people everywhere to live healthier lives by transforming the healthcare experience. Recognized as the world leader in whole-person virtual care, Teladoc Health addresses the full spectrum of health and well-being — powered by human expertise, advanced technology and insights—to deliver improved clinical outcomes at scale. Serving more than 175 countries and...
Teladoc Health's Top Stability & Growth Strengths
Strong Market Position & Advantage: Scale across enterprise and direct‑to‑consumer channels (including 17.1 million visits in 2025) and a broad integrated‑care stack position the company as a top multi‑specialty virtual‑care operator. External signals such as BetterHelp’s category scale and a top‑tier satisfaction ranking support durable competitive standing.
Cost & Operational Efficiency: Operating performance shows improving efficiency with a materially narrower net loss and stable adjusted EBITDA despite revenue pressure. Margin expansion in Integrated Care indicates better unit economics at scale.
Market Expansion: International revenue grew while insurance acceptance for BetterHelp expanded and new channels were pursued, signaling ongoing market expansion. These moves diversify geography and payer mix beyond U.S. cash‑pay exposures.
Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly...
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world....
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to...
LivaNova's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate revenue rose at a double‑digit pace in 2025 and into early 2026, with management increasing full‑year growth guidance. Filings attribute momentum to broad strength across Cardiopulmonary and Neuromodulation.
Strong Market Position & Advantage: Evidence points to leadership in implantable VNS and a top‑tier position in cardiopulmonary perfusion, supported by a large installed base and competitor retrenchment. Independent coverage and recognition of pivotal studies reinforce defensible share within chosen niches.
Product Line Growth: Commercial uptake of the Essenz Perfusion System and steady consumables demand are driving cardiopulmonary expansion. Approval of the aura6000 device for obstructive sleep apnea and a connected‑care VNS roadmap add incremental growth avenues.
We’re Medmate. Nice to meet you. We take the inconvenience and awkwardness out of pharmacy visits. Book a consultation with a doctor or get a script all online. It's fast, easy and convenient. Medmate was developed by doctors and pharmacists and born out of a desire to take the burden out of pharmacy shopping and make life that little bit...
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
Aravax is a clinical stage biotechnology company developing a novel peptide-based immunotherapy, PVX108, for the treatment of peanut allergy. Aravax is striving to improve the lives of patients living with peanut allergies by developing a therapy that precisely targets the underlying cause of disease, bringing benefits in safety and convenience.
MedHealth is a purpose-built collection of industry-leading health, medical, and employment brands that leverage diverse capabilities to deliver optimal health and employment outcomes for the people and communities they support.
Integra LifeSciences, a world leader in medical technology with headquarters in Princeton, New Jersey, was founded in 1989 with the acquisition of an engineered collagen technology platform used to repair and regenerate tissue. Since then, Integra has expanded its base regenerative technology product portfolio to include surgical instruments, neurosurgical products and advanced wound care products, through global acquisitions and development...
Nanochap is a fabless semiconductor company with its core R&D team based in Melbourne, Australia. We specialise in neural interface and biosensing SoCs. The company is committed to the R&D, design, packaging, testing, and commercialisation of ultra-high density neural interface chips, biosensing chips, and other medical device related chips.
Mable is a health-tech platform where people looking for disability and aged care support connect with independent support workers in their community. As one of Australia’s fastest-growing scale-ups, we think big to spearhead change in our sector. We're passionate about inclusivity and giving choice and control back to those who need it. Mable launched in 2014 when co-founder Peter Scutt...
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed...
Nucleus Global is the largest specialist medical communications company in the world. Built on a reputation of scientific excellence and quality, we are a global leader in delivering world-class, innovative education and medical marketing services to the pharmaceutical and biotechnology industries.
Montu is Australia's leading health tech business revolutionising the alternative health landscape. Montu has built an integrated ecosystem, which streamlines the experience for patients end-to-end, and sets new standards. The company is committed to improve the lives of millions of patients
